@article{CJCR1378,
author = {Zhaode Bu and Zhixue Zheng and Lianhai Zhang and Ziyu Li and Yu Sun and Bin Dong and Aiwen Wu and Xiaojiang Wu and Xiaohong Wang and Xiaojing Cheng and Xiaofang Xing and Yingai Li and Hong Du and Jiafu Ji},
title = {LGR5 is a promising biomarker for patients with stage I and II gastric cancer},
journal = {Chinese Journal of Cancer Research},
volume = {25},
number = {1},
year = {2013},
keywords = {},
abstract = {Objective: To investigate Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) expressions in gastric cancer and to evaluate its clinical significance.
Methods: LGR5 expression was assessed by immunohistochemistry in 257 gastric cancer patients after surgery. The relationships between LGR5 expression and clinicopathological features and patients prognosis were statistically analyzed.
Results: The expression of LGR5 was significantly higher in gastric cancers as a cancer stem cell marker than in adjacent normal tissues (P<0.001), and more frequently in patients with intestinal type, well-moderate differentiation and stage I and II (P<0.05). Although we found gastric cancer patients with LGR5 positive expression had a poorer prognosis, it didn’t meet statistical significance (P>0.05). LGR5 negative expression was significantly related to the favorable overall survival in stage I and II gastric cancer patients (P<0.05). Furthermore, patients with high LGR5 expression tended to be more likely to get progression and have poorer progress-free survival (P<0.05). Multivariate Cox regression analysis revealed that LGR5 expression was an independent factor of overall survival for the patients with stage I and II gastric cancer (P<0.05).
Conclusions: Our results show that LGR5 may play an important role in tumorigenesis and progression and would be a powerful marker to predict the prognosis of patients with stage I and II gastric cancer.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/1378}
}